JP2019523305A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523305A5
JP2019523305A5 JP2019526375A JP2019526375A JP2019523305A5 JP 2019523305 A5 JP2019523305 A5 JP 2019523305A5 JP 2019526375 A JP2019526375 A JP 2019526375A JP 2019526375 A JP2019526375 A JP 2019526375A JP 2019523305 A5 JP2019523305 A5 JP 2019523305A5
Authority
JP
Japan
Prior art keywords
particle size
tolucapon
transthyretin
malvern
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019526375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523305A (ja
JP7047236B2 (ja
Filing date
Publication date
Priority claimed from EP16382372.7A external-priority patent/EP3275433A1/en
Application filed filed Critical
Publication of JP2019523305A publication Critical patent/JP2019523305A/ja
Publication of JP2019523305A5 publication Critical patent/JP2019523305A5/ja
Application granted granted Critical
Publication of JP7047236B2 publication Critical patent/JP7047236B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019526375A 2016-07-29 2017-07-28 微粒子化トルカポンを含む徐放性錠剤 Active JP7047236B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382372.7A EP3275433A1 (en) 2016-07-29 2016-07-29 Sustained release composition comprising micronized tolcapone
EP16382372.7 2016-07-29
PCT/EP2017/069168 WO2018019997A1 (en) 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone

Publications (3)

Publication Number Publication Date
JP2019523305A JP2019523305A (ja) 2019-08-22
JP2019523305A5 true JP2019523305A5 (https=) 2020-08-13
JP7047236B2 JP7047236B2 (ja) 2022-04-05

Family

ID=56571284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019526375A Active JP7047236B2 (ja) 2016-07-29 2017-07-28 微粒子化トルカポンを含む徐放性錠剤

Country Status (12)

Country Link
US (2) US11883538B2 (https=)
EP (2) EP3275433A1 (https=)
JP (1) JP7047236B2 (https=)
KR (1) KR102484678B1 (https=)
CN (1) CN109789100A (https=)
AU (1) AU2017303333B2 (https=)
DK (1) DK3490535T3 (https=)
ES (1) ES2891355T3 (https=)
MX (1) MX391116B (https=)
PT (1) PT3490535T (https=)
RU (1) RU2750670C2 (https=)
WO (1) WO2018019997A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
BR9710448A (pt) * 1996-05-20 1999-08-17 Searle & Co Formula-{es farmac-uticas de sal de pot ssio sÄdioe tris oxaprozina
KR20010042566A (ko) 1998-04-09 2001-05-25 프리돌린 클라우스너, 롤란드 비. 보레르 압축된 기체 및 계면활성제중에 용해시킴으로써, 크기가마이크론 이하인 입자를 제조하는 방법
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
CA2510319A1 (en) * 2002-12-20 2004-07-15 Thomas J. Smith High pressure compaction for pharmaceutical formulations
EA013161B1 (ru) * 2005-06-08 2010-02-26 Орион Корпорейшн Дозированная форма для перорального применения
JPWO2008087882A1 (ja) * 2007-01-15 2010-05-06 キッセイ薬品工業株式会社 胃内滞留型レボドパ徐放性製剤
EP2640358B1 (en) 2010-11-15 2018-01-03 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
CA2835617C (en) 2011-03-14 2020-07-21 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production
RU2747536C2 (ru) * 2011-10-24 2021-05-06 Сом Инновэйшн Биотек, С.Л. Новая терапия транстиретин-ассоциированного амилоидоза
US20130195973A1 (en) * 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
PT2968218T (pt) * 2013-03-13 2021-09-24 Neuroderm Ltd Combinação para tratamento da doença de parkinson
KR102457026B1 (ko) * 2013-11-05 2022-10-21 신애질 코포레이션 입을 통한 연속적 약물 전달
PT3782617T (pt) * 2014-09-04 2024-02-29 Lobsor Pharmaceuticals Ab Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona

Similar Documents

Publication Publication Date Title
JP2015096530A5 (https=)
JP2015525757A5 (https=)
WO2014160441A8 (en) Neuroactive steroids, compositions, and uses thereof
JP2012143233A5 (https=)
JP2019508789A5 (https=)
WO2016168784A3 (en) Rna nanoparticles and method of use thereof
JP2014237817A5 (https=)
JP2014530840A5 (https=)
WO2015023681A3 (en) Swallowing assessment and improvement systems and methods
HK1206028A1 (en) Phenicol antibacterials
JP2016135110A5 (https=)
EP2978420A4 (en) STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
JP2014022036A5 (https=)
WO2016142708A3 (en) Pharmaceutical composition
WO2016140933A3 (en) Immediate release soluble ibuprofen compositions
JP2016540019A5 (https=)
CY1121986T1 (el) Στερεη φαρμακευτικη συνθεση κυtισινης και διαδικασια για την παρασκευη της
HK1209371A1 (en) Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same
EP2978428A4 (en) STABLE NANO COMPOSITION WITH EPIRUBICIN, PROCESS FOR THE PRODUCTION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
FR3011547B1 (fr) Materiau composite solide alveolaire comportant des nanoparticules metalliques, procede de preparation et utilisations pour le stockage reversible de l'hydrogene
JP2019094312A5 (https=)
JP2019523305A5 (https=)
WO2013024494A3 (en) Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone
HK1245155A1 (zh) 制备去氧肾上腺素树脂酸盐颗粒的方法;去氧肾上腺素树脂酸盐颗粒;以及去氧肾上腺素树脂酸盐颗粒在药物制剂中的用途
HK1203379A1 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF